65 related articles for article (PubMed ID: 11738123)
1. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Pressel S; Davis BR; Louis GT; Whelton P; Adrogue H; Egan D; Farber M; Payne G; Probstfield J; Ward H;
Control Clin Trials; 2001 Dec; 22(6):674-86. PubMed ID: 11738123
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Dewland TA; Soliman EZ; Yamal JM; Davis BR; Alonso A; Albert CM; Simpson LM; Haywood LJ; Marcus GM
Circ Arrhythm Electrophysiol; 2017 Dec; 10(12):. PubMed ID: 29212812
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
[TBL] [Abstract][Full Text] [Related]
4. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
[TBL] [Abstract][Full Text] [Related]
5. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).
Alderman MH; Davis BR; Piller LB; Ford CE; Baraniuk MS; Pressel SL; Assadi MA; Einhorn PT; Haywood LJ; Ilamathi E; Oparil S; Retta TM;
Am J Cardiol; 2016 Jan; 117(1):105-15. PubMed ID: 26589819
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
Du XL; Simpson LM; Tandy BC; Bettencourt JL; Davis BR
PLoS One; 2021; 16(11):e0260107. PubMed ID: 34793552
[TBL] [Abstract][Full Text] [Related]
7. Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended.
Du XL; Simpson LM; Tandy BC; Bettencourt J; Davis BR
Int J Hypertens; 2021; 2021():2261144. PubMed ID: 34925915
[TBL] [Abstract][Full Text] [Related]
8. The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT-Medicare linked data.
Du XL; Martinez J; Yamal JM; Simpson LM; Davis BR
Front Cardiovasc Med; 2023; 10():1272385. PubMed ID: 38045916
[TBL] [Abstract][Full Text] [Related]
9. Comments on ALLHAT and doxazosin.
Krakoff LR
Curr Control Trials Cardiovasc Med; 2001; 2(6):254-256. PubMed ID: 11806807
[TBL] [Abstract][Full Text] [Related]
10. Commentary: The ALLHAT Study: implications for the management of resistant hypertension.
Singer GM; Setaro JF
J Clin Hypertens (Greenwich); 2005 Jan; 7(1):31-2. PubMed ID: 15655384
[No Abstract] [Full Text] [Related]
11. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
12. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial.
Soliman EZ; Byington RP; Bigger JT; Evans G; Okin PM; Goff DC; Chen H
Hypertension; 2015 Dec; 66(6):1123-9. PubMed ID: 26459421
[TBL] [Abstract][Full Text] [Related]
13. ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
Elliott WJ
Am J Hypertens; 1996 Apr; 9(4 Pt 1):409-11. PubMed ID: 8722446
[No Abstract] [Full Text] [Related]
14. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
[TBL] [Abstract][Full Text] [Related]
15. A Community and Technology-Based Approach for Hypertension Self-Management (COACHMAN) to Improve Blood Pressure Control in African Americans: Results from a Pilot Study.
Still CH; Margevicius S; Harwell C; Huang MC; Martin L; Dang PB; Wright Jnr JT
Patient Prefer Adherence; 2020; 14():2301-2313. PubMed ID: 33262580
[TBL] [Abstract][Full Text] [Related]
16. Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT.
Shahu A; Herrin J; Dhruva SS; Desai NR; Davis BR; Krumholz HM; Spatz ES
J Am Heart Assoc; 2019 Aug; 8(15):e012277. PubMed ID: 31362591
[TBL] [Abstract][Full Text] [Related]
17. Conditional moving linear regression: modeling the recruitment process for ALLHAT.
Lai D; Zhang Q; Yamal JM; Einhorn PT; Davis BR;
Commun Stat Theory Methods; 2017; 46(18):8943-8951. PubMed ID: 30906106
[TBL] [Abstract][Full Text] [Related]
18. Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Shams T; Auchus AP; Oparil S; Wright CB; Wright J; Furlan AJ; Sila CA; Davis BR; Pressel S; Yamal JM; Einhorn PT; Lerner AJ;
Stroke; 2017 Nov; 48(11):3078-3085. PubMed ID: 28954920
[TBL] [Abstract][Full Text] [Related]
19. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS;
JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241
[TBL] [Abstract][Full Text] [Related]
20. Recruitment strategies and challenges in a large intervention trial: Systolic Blood Pressure Intervention Trial.
Ramsey TM; Snyder JK; Lovato LC; Roumie CL; Glasser SP; Cosgrove NM; Olney CM; Tang RH; Johnson KC; Still CH; Gren LH; Childs JC; Crago OL; Summerson JH; Walsh SM; Perdue LH; Bankowski DM; Goff DC;
Clin Trials; 2016 Jun; 13(3):319-30. PubMed ID: 26911833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
